Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Shanghai Obio Technology (Group)'s Debt-to-EBITDA or its related term are showing as below:
SHSE:688238'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.3 Med: -0.64 Max: 1.97
Current: -2.04
During the past 8 years, the highest Debt-to-EBITDA Ratio of Shanghai Obio Technology (Group) was 1.97. The lowest was -3.30. And the median was -0.64.
SHSE:688238's Debt-to-EBITDA is ranked worse than 100% of 304
companies
in the Biotechnology industry
Industry Median: 1.215
vs SHSE:688238: -2.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shanghai Obio Technology (Group) Debt-to-EBITDA Related Terms
Shanghai Obio Technology (Group) Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688238 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Shanghai Obio Technology (Group)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Obio Technology (Group) Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Obio Technology (Group)'s Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shanghai Obio Technology (Group)'s Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Shanghai Obio Technology (Group) (SHSE:688238) has a Debt-to-EBITDA of -3.74 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Obio Technology (Group). According to the industry distribution chart, Shanghai Obio Technology (Group) ranks #999999 out of 304 companies in the Biotechnology industry.
Is Shanghai Obio Technology (Group)'s Debt-to-EBITDA too high?
Shanghai Obio Technology (Group)'s current Debt-to-EBITDA is -3.74. Based on the distribution chart, Shanghai Obio Technology (Group) ranks #999999 out of 304 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Obio Technology (Group) has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Obio Technology (Group)'s Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Obio Technology (Group) ranks #999999 out of 304 companies for Debt-to-EBITDA. This places Shanghai Obio Technology (Group) in the lower half of its industry. The industry median Debt-to-EBITDA is 1.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Obio Technology (Group). For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Obio Technology (Group)'s current Debt-to-EBITDA is -3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Obio Technology (Group) stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Obio Technology (Group) (SHSE:688238) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.58, compared to a current price of ¥7.84 — trading 3.4% above its estimated fair value. The current Debt-to-EBITDA is -3.74. Shanghai Obio Technology (Group)'s overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shanghai Obio Technology (Group) (SHSE:688238), the current Debt-to-EBITDA is -3.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Obio Technology (Group) (SHSE:688238) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Obio Technology (Group) stock appears to be overvalued.
The current stock price of ¥7.84 is trading 3.4% above its estimated GF Value™ of ¥7.58.
GuruFocus considers Shanghai Obio Technology (Group) to be Fairly Valued.
Key valuation signals for SHSE:688238:
Debt-to-EBITDA: -3.74
GF Value™: ¥7.58 vs. price of ¥7.84 (3.4% above fair value)
No single metric tells the full story. See the SHSE:688238 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Obio Technology (Group) Corp Ltd is a Chinese biotechnology services company that provides contract research organization (CRO) and contract development and manufacturing organization (CDMO) services focused on gene therapy and cell therapy. Its CRO offerings include gene function research, vector design and construction, and preclinical studies supporting basic research and drug discovery. Its CDMO segment covers process development, IND-enabling CMC research, and GMP manufacturing of clinical-grade vectors and plasmids for gene therapy developers. The company primarily serves pharmaceutical and biotechnology companies, research institutes, universities, and hospitals in China and internationally. Revenue is generated mainly through fee-for-service research contracts and manufacturing agreements, with project-based and milestone-linked arrangements. The company operates research and production facilities in China and has expanded its capabilities in adeno-associated virus and lentiviral vector production to support clients advancing gene therapy candidates toward clinical trials.
69GF Score
Get the complete analysis for SHSE:688238
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688238 has been successfully added to your 
